COMMUNIQUÉS West-GlobeNewswire

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
25/08/2026
PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite [...]
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
25/08/2026
Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication [...]
electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
25/08/2026
Recognition highlights Truvaga’s combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience ROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- [...]
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
25/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today [...]
4DMT to Participate in Upcoming Investor Conferences
25/08/2026
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
25/08/2026
Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome [...]
Nu-Tek BioSciences participera au salon BPI East 2026 à Boston pour établir des liens entre ses nutriments pour milieux de culture sans composants d’origine animale et les stratégies de croissance de ses clients du secteur pharmaceutique
25/08/2026
Nu-Tek rencontrera des dirigeants de l’industrie pharmaceutique lors du salon BioProcess International East, du 22 au 25 septembre à Boston, afin de discuter de peptones et d’hydrolysats de protéines 100 % sans [...]
Nu-Tek BioSciences to Attend BPI East 2026 in Boston, Connecting Animal-Free Culture Media Nutrients with Pharma Customer Growth Strategies
25/08/2026
Nu-Tek will meet with pharmaceutical leadership during BioProcess International East Sept. 22-25 in Boston to discuss 100% animal-origin-free peptones and protein hydrolysates, with a focus on product quality and supply [...]
Mixie Technologies, Inc. (OTC: MIXE) Portfolio Company HoloTwin Unveils TwinRuntime: Enterprise Digital Twins That Run in a Standard Web Browser, No Downloads Required
25/08/2026
Mixie Technologies' flagship portfolio company milestone caps a year that took HoloTwin from a strategic investment, to a CES 2026 award, to HoloTwin 2.0, and now to a browser-native runtime that puts living digital [...]
CVRx Responds to Letter from Pointillist Family Office
25/08/2026
MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
25/08/2026
TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic [...]
Annovis to Host Corporate Update Webinar on September 2, 2026
25/08/2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
25/08/2026
Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
25/08/2026
Presentation addressed potential applications in prolonged field care and military wound management settings WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or [...]
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
25/08/2026
Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology WARSAW, Ind., Aug. 25, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics) (Nasdaq: KIDS), a company [...]
Ocugen to Participate in Upcoming September Investor and Industry Conferences
25/08/2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
25/08/2026
Multidisciplinary panel publishes 30 consensus statements to improve communication and shared decision-making in neuroblastoma care WEST CONSHOHOCKEN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a [...]
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
25/08/2026
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, [...]
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
25/08/2026
Enrollment and dosing completed in Phase 1 randomized controlled trial (n=144) evaluating the safety, tolerability, immunogenicity and cross-species activity of APL-10456, an investigational rhinovirus vaccine Initial [...]

Pages